CCBIO Seminar – Mika Kontro
Velkommen til CCBIOs seminarserie for vårsemesteret 2024. Åpent for alle i auditorium 4, BBB. Påmelding er ikke nødvendig. Foreleser er Mika Kontro fra Universitetet i Helsinki, med emnet «Functional Screening for Precision Medicine Approaches in Acute Myeloid Leukemia».
Hovedinnhold
(Videre tekst på engelsk siden seminarene er internasjonale, og undervisningsspråket er engelsk.)
Speaker: Dr. Mika Kontro, University of Helsinki, Finland
Mika Kontro, MD, PhD is an adjunct professor and a consultant in clinical hematology at the Helsinki University Hospital Comprehensive Cancer Center. Mika Kontro earned his PhD thesis, entitled “Individualizing therapy for acute leukemia”, in 2017.
He currently works as K. Albin Johannson Cancer Research Fellow (Finnish Cancer Institute) and as a group leader in FIMM. He has a strong background in running clinical trials and was selected at 2017 for European Hematology Association Clinical Research Training program (CRTH). Mika Kontro currently chairs the Finnish AML group and is a board member of the Nordic AML Group. Currently he leads a prospective multi-center AML trial VenEx utilizing ex-vivo drug sensitivity testing for individualized patient care.
Title: Functional Screening for Precision Medicine Approaches in Acute Myeloid Leukemia
Host: Bjørn Tore Gjertsen
Where: Auditorium 4, BB-building
When: March 21, 2024 at 14.30-15.30
No registration necessary.
Abstract: Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore, Dr. Kontro will focus on the VenEx trial, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen.